UNITED STATES OF AMERICA —A major buyout in the healthcare manufacturing sector will see Lifecore Biomedical transition to private ownership under Webster Equity Partners through an acquisition agreement valued at up to $663.7 million. Common shareholders are set to receive $6.28 per share in upfront cash, a 49.5% premium over recent market prices alongside non-tradable contingent value rights tied to milestone performance targets through 2030. Holders of preferred stock will also receive cash considerations based on conversion values plus milestone rights. The agreement features a 30-day window allowing the target business to evaluate alternative proposals, with transaction completion targeted for the final quarter of 2026 pending regulatory approvals and shareholder consent.
Lifecore Biomedical is a Minnesota-headquartered contract development and manufacturing organization specializing in sterile injectable pharmaceutical products and premium injectable-grade hyaluronic acid, serving global biotechnology and pharmaceutical firms across various therapeutic sectors. Webster Equity Partners is a Massachusetts-based private equity investment firm focused exclusively on healthcare services companies.
This private equity takeover highlights growing investor appetite for specialized pharmaceutical contract development and manufacturing assets capable of handling complex formulations. By securing debt and equity funding commitments, the deal provides the essential capital required to scale sterile fill-and-finish production lines for injectable therapies, syringes, and cartridges. Contract drug manufacturers are navigating heightened regulatory oversight and growing demand for specialized commercialization capabilities, making institutional backing vital for capacity expansion.
For the broader pharmaceutical supply chain, the transition underscores how private equity firms are deploying capital into critical outsourcing partners to leverage long-term commercialization pipelines. The structure of the deal, which hinges significant financial upside on revenue and earnings benchmarks through 2030, aligns investor payouts directly with operational scaling and client onboarding. This transaction highlights a broader strategic trend of private capital absorbing specialized CDMOs to finance multi-year growth trajectories free from public market scrutiny.
